Survey and Pre-Test Name*Email* My degree is:*MD or DOMD, PhDPhDPharmDBS-PharmacyRNNPPAWhich of the following best describes your specialty?*Hematologic oncologyMedical oncologyHematologyNursingPharmacyMy practice setting is*AcademicCommunityHow many patients with hematologic malignancies do you treat each week on average?*None1-56-1011-1516-20>20Which of the following is an adverse event associated with the use of CAR T-cells in ALL?*B-cell aplasiaTumor lysis syndromeMacrophage activation syndromeAll of the aboveA and B onlyWhich is associated with the highest response rate?*CTLA-4 blockade in DLBCLCTLA-4 blockade in HLPD-1 blockade in DLBCLPD-1 blockade in HLPD-1 blockade in PMBCLPD-L1 is expressed predominantly on?*Tumor cellsEffector T-cellsRegulatory T-cellsDendritic cellsPrior to this activity, how likely are you to use immunotherapies for the treatment of patients with hematologic malignancies?*Very likelyLikelySomewhat likelyUnlikelyWould you like to voluntarily opt-in to receive future correspondence on Bio Ascend programming?*YesNoPhoneThis field is for validation purposes and should be left unchanged. This iframe contains the logic required to handle AJAX powered Gravity Forms.